Australia's most trusted
source of pharma news
Tuesday, 22 October 2024
Posted 22 May 2024 AM
Australia's second largest ASX-listed biotech by market cap, Telix Pharmaceuticals, is looking to the US for further investment.
On Friday, the Melbourne headquartered diagnostic and therapeutic radiopharmaceuticals developer filed a registration statement with the Securities and Exchange Commission (SEC) for an initial public offering (IPO) of its American Depositary Shares (ADSs) on the Nasdaq Global Market.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.